Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Flt-3


Brief Information

Name:Tyrosine-protein kinase receptor FLT3
Target Synonym:EC:,CD135 Antigen,CD135,STK1,Growth Factor Receptor Tyrosine Kinase Type III,Fms-Related Tyrosine Kinase 3,Fetal Liver Kinase 2,Fetal Liver Kinase-2,EC,fms-Like Tyrosine Kinase 3,Receptor-type tyrosine-protein kinase FLT3,FLT3,FLT-3,FLK2,STK-1,FL cytokine receptor,Fms Related Tyrosine Kinase 3,Stem Cell Tyrosine Kinase 1,FLK-2,Fms Related Receptor Tyrosine Kinase 3,EC 2.7.10
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:37
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Biotinylated Human Flt-3, His,AvitagBiotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) ELISA bioactivity

Immobilized Human Flt-3 Ligand, His Tag (Cat. No. FLL-H5223) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Biotinylated Human Flt-3, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) is more than 90% and the molecular weight of this protein is around 97-119 kDa verified by SEC-MALS.

Biotinylated Human Flt-3, His,AvitagBiotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) ELISA bioactivity

Immobilized Human Flt-3 Ligand, His Tag (Cat. No. FLL-H5223) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Synonym Name



Flt-3(Receptor-type tyrosine-protein kinase FLT3) is also known as FLK-2(Fetal liver kinase-2), STK-1(Stem cell tyrosine kinase 1), CD135. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Quizartinib AC-220; ASP-2689; AC-010220 Approved Ambit Biosciences Vanflyta Japan Leukemia, Myeloid, Acute Daiichi Sankyo Co Ltd 2019-06-18 Leukemia, Myeloid, Acute Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc Nexavar, 多吉美 EU Thyroid Neoplasms Bayer AG 2005-12-01 Lung Neoplasms; Adrenocortical Carcinoma; Mesothelioma; Breast Neoplasms; Hepatitis B; Prostatic Neoplasms; Brain Neoplasms; Sarcoma; Pulmonary Arterial Hypertension; Medullary thyroid cancer (MTC); Hepatitis C; Thyroid Neoplasms; Leukemia, Monocytic, Acute; Lymphoma, T-Cell; Digestive System Neoplasms; Leukemia, Myeloid, Acute; Glioma; Venous Thrombosis; Facial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Adenocarcinoma; Fasting; Leukemia, Biphenotypic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms; Ovarian Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Kidney Neoplasms; Recurrence; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Abdominal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Liver Neoplasms; Neoplasms, Glandular and Epithelial; Kidney Diseases; Myelodysplastic Syndromes; Myeloproliferative Disorders; Thyroid Details
Pexidartinib PLX-3397 Approved Daiichi Sankyo Co Ltd Turalio United States Giant Cell Tumor of Tendon Sheath Daiichi Sankyo Inc 2019-08-02 Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Hodgkin Disease; Glioblastoma; Neoplasms; Giant Cell Tumors; Prostatic Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Melanoma Details
Ponatinib Hydrochloride AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 Approved Ariad Iclusig Japan Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Otsuka Holdings Co Ltd 2012-12-14 Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Gastrointestinal Stromal Tumors; Philadelphia Chromosome; Medullary thyroid cancer (MTC); Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Blast Crisis; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia; Hematologic Neoplasms Details
Brigatinib AP-26113 Approved Ariad, Takeda Pharmaceutical Co Ltd Alunbrig Mainland China Carcinoma, Non-Small-Cell Lung Takeda (China) International Trading Co Ltd 2017-04-28 Solid tumours; Ependymoma; Carcinoma; Neurofibromatosis 2; Neoplasms; Myofibroma; Granuloma, Plasma Cell; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Carcinoma, Non-Small-Cell Lung; Meningioma; Neurilemmoma; Neuroma, Acoustic Details
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Thyroid Neoplasms; Adenocarcinoma, Follicular; Brain Neoplasms; Sarcoma; Neuroblastoma; Neurofibroma, Plexiform; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Bile Duct Neoplasms; Central Nervous System Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Neoplasms, Germ Cell and Embryonal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Thyroid Cancer, Papillary; Meningioma; Carcinoma, Transitional Cell; Kidney Neoplasms; Ovarian germ cell tumor; Bone metastases; Carcinoma, Renal Cell; Rejection of liver transplantation; Esophageal Neoplasms; Pain; Stomach Neoplasms; Carcinoma, Merkel Cell; Glioblastoma; Seminoma; Solid tumours; Neurofibromatoses; Neoplasms; Salivary Gland Neoplasms; Carcinoma, Papillary; Skin Neoplasms; Kidney Diseases; Neuroendocrine Tumors; Adrenocortical Carcinoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma Details
Fedratinib TG-101348; SAR-302503 Approved Sanofi Inrebic EU Primary Myelofibrosis; Splenomegaly Bristol Myers Squibb Srlcompany 2019-08-16 Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Myeloproliferative Disorders; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Genital Neoplasms, Female; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Oligodendroglioma; Bronchitis; Silicosis; Gliosarcoma; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Idiopathic Pulmonary Fibrosis; Head and Neck Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Bronchiolitis Obliterans; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rejection of lung transplantation; Carcinoma, Renal Cell; Scleroderma, Systemic; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Glioblastoma; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis Details
Gilteritinib Fumarate ASP-2215; 66D-92MGC8M (UNII code); ASP-2215 hemifumarate Approved Astellas Pharma Inc Xospata Mainland China Leukemia, Myeloid, Acute Astellas Pharmaceutical (China) Co Ltd 2018-09-21 Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute Details
Pacritinib SB-1518; ONX-0803 Approved Syncore Biotechnology Co Ltd, Concert VONJO United States Primary Myelofibrosis Cti Biopharma Corp 2022-02-28 Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Thrombocytopenia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Lymphoproliferative Disorders; Colorectal Neoplasms; Primary Myelofibrosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Coronavirus Infections; Lymphoma, Mantle-Cell; Coronavirus Disease 2019 (COVID-19); Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myeloproliferative Disorders; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, T-Cell, Peripheral; Leukemia; Lymphoma, B-Cell Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt Approved Pfizer Pharmaceuticals Ltd (China) 索坦, Sutent Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Diabetic macular oedema; Thyroid Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Peritoneal Neoplasms; Astrocytoma; Thymus Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Thymoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Prostatic Neoplasms; Sarcoma; Breast Neoplasms; Adrenocortical Carcinoma; Adenocarcinoma; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Retinal Vein Occlusion; Meningioma; von Hippel-Lindau Disease; Neoplasm Metastasis; Macular Degeneration; Carcinoma, Hepatocellular; Adenocarcinoma, Follicular; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Neoplasms, Gonadal Tissue; Nervous System Neoplasms; Germinoma; Brain metastases; Hemangiopericytoma; Urogenital Neoplasms; Hemangioblastoma; Glioblastoma; Pheochromocytoma; Pelvic Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Islet Cell; Histiocytom Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Sorafenib Tosylate/MG-K10 MG-D-1609 Phase 2 Clinical Metagone Biotech Solid tumours Details
SEL-24 SEL-24 program; SEL-24; MEN-1703; SEL-24-1; SEL-24-B489 Selvita Details
Luxeptinib CG-806; CG-026806 Crystalgenomics Inc, Aptose Details
RIVAL-01 TBio-6517; TAK-605 Takeda Pharmaceutical Co Ltd, Turnstone Biologics Inc Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
SKI-G-801 G-801; SKI-G-801; G-749 Hydrochloride Oscotec Details
Flonoltinib maleate Phase 1 Clinical Chengdu Zenitar Biomedical Technology Co Ltd Myeloproliferative Disorders Details
LM-061 LM-061 Phase 1 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Solid tumours Details
GS-3583 GS-3583 Gilead Sciences Inc Details
FF-10101 FF-10101; FF-10101-01; FF-10101 succinate Fujifilm Corp Details
AT-9283 AT-9283 Otsuka Pharmaceutical Co Ltd Details
ETH-155008 ETH-155008 Phase 1 Clinical Yunnan Shengke Pharmaceutical Co Ltd Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute Details
SU-014813 SU-14813; SU-014813 Pfizer Pharmaceuticals Ltd (China) Details
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Kyowa Hakko Kirin Details
KC1036 KC1036; KC-1036 Phase 2 Clinical Beijing Konruns Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Neoplasm Metastasis Details
XL-999 XL-999; EXEL-0999 Symphony Evolution, Exelixis, Glaxosmithkline Plc Details
Flysyn 4G8-SDIEM Synimmune Details
FLX-925 AMG-925; FLX-925 Amgen Inc Details
XY0206 XY-0206 Phase 1 Clinical Shijiazhuang Yiling Pharmaceutical Co Ltd, Nanjing University Of Chinese Medicine Solid tumours; Leukemia, Myeloid, Acute Details
HM-43239 Hanmi Pharmaceutical Co Ltd Details
Emirodatamab AMG-427 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
KW-2449 KW-2449 Kyowa Hakko Kirin Hematologic Neoplasms Details
AKN-028 BVT-II; AKN-028; BVT-63628 Akinion Details
AMG-553 AMG-553 Amgen Inc Details
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) CDX-301 Amgen Inc Details
AGS-62P1 AGS62P1; ASP-1235 Ambrx Inc Details
Zotiraciclib TG-02; SB-1317 Phase 2 Clinical Syncore Biotechnology Co Ltd Glioblastoma; Brain Neoplasms; Gliosarcoma; Astrocytoma; Glioma Details
Emavusertib CA-4948; AU-4948 Aurigene Details
MRX-2843 MRX-2843; UNC-2025; UNC-2371 Phase 1 Clinical Meryx, University Of North Carolina At Chapel Hill, University Of Colorado At Denver Solid tumours; Leukemia, Myeloid, Acute Details
SC-71710 4SC-203; SC-71710 4sc Ag, Proqinase Details
Tozasertib VX-680; MK-0457 Vertex Pharmaceuticals Incorporated Details
SGI-1776 SG-0407; SGI-1776 Astex Pharmaceuticals Inc Details
HYML-122 HYML-122; CHMFL-FLT3-122 Phase 2 Clinical Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals Leukemia, Myeloid, Acute Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 1 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
Sorafenib/MG-005 MGD-1509; MG-D-1509 Metagone Biotech, Tri-Service General Hospital Details
PLX-7486 PLX-7486; PLX7486-TsOH Daiichi Sankyo Co Ltd Details
Mivavotinib TAK-659; CB-659 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Solid tumours; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Lymphoma, Follicular; Plasmablastic Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) TAA05 Phase 2 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Leukemia, Myeloid, Acute Details
SKLB-1028 SKLB-1028 Phase 3 Clinical Sichuan University, CSPC Pharmaceutical Group Ltd Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute Details
FN-1501 FN-1501; LT-171-861 Phase 2 Clinical China Pharmaceutical University, Shanghai Fosun Pharmaceutical Development Ltd Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular Details
Clifutinib Besylate Phase 2 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
Crenolanib Besylate CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Stromal Tumors; Diffuse Intrinsic Pontine Glioma; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Non-Small-Cell Lung Details
E-6201 E-6201 Phase 1 Clinical Eisai Co Ltd Solid tumours; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
NMS-03592088 NMS-P088; NMS-03592088 Phase 2 Clinical Nerviano Medical Sciences Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Cholangiocarcinoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Thyroid Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Nasopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Carcinoma, Renal Cell; Solid tumours; Biliary Tract Neoplasms Details
HH-30134 HH-30134 Phase 1 Clinical ShangHai HaiHe Biopharma Co Ltd Solid tumours; Neoplasms Details
MAX-40279 MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 Phase 2 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Leukemia; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis Details
TT-00973 TT-00973 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message